Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Palivizumab.

L J Scott1, H M Lamb

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 3, 1999
PubMed
Summary
This summary is machine-generated.

Palivizumab, a monoclonal antibody, significantly reduces hospitalizations in high-risk infants due to respiratory syncytial virus (RSV) lower respiratory tract infections. This treatment is well-tolerated and effective in preventing severe RSV disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of traumatic brain injury amongst secondary school students in England: A retrospective cohort study using electronic health records.

Injury·2026
Same author

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Systematic review of interventions for the prevention and treatment of postoperative urinary retention.

BJS open·2019
Same author

Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same author

The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Immunology
  • Pediatrics
  • Virology

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants.
  • Infants at high risk require effective preventive strategies against severe RSV disease.

Purpose of the Study:

  • To evaluate the efficacy and safety of palivizumab for preventing serious lower respiratory tract disease caused by RSV in high-risk infants.
  • To assess the impact of palivizumab on RSV-attributable hospitalizations and clinical outcomes.

Main Methods:

  • A large multicenter trial involving 1502 high-risk infants.
  • Administration of intramuscular palivizumab at 15 mg/kg compared to placebo.
  • Monitoring of RSV-attributable hospitalizations, hospital days, oxygen requirements, and intensive care admissions.

Related Experiment Videos

Main Results:

  • Palivizumab more than halved the incidence of RSV-attributable hospitalizations (4.8% vs. 10.6%).
  • Significant reductions were observed in total hospital days, supplemental oxygen needs, and intensive care admissions.
  • Adverse event incidence was similar between palivizumab and placebo groups, with fever, irritability, and injection site reactions being most common.

Conclusions:

  • Palivizumab is an effective and well-tolerated prophylactic measure against serious lower respiratory tract disease caused by RSV in high-risk infants.
  • The drug demonstrates significant clinical benefits, reducing hospitalization rates and associated morbidity.